# ATI-045 Versus Placebo in Patients With Moderate-to-Severe Atopic Dermatitis

> **NCT07011706** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Aclaris Therapeutics, Inc.** · enrollment: 110 (actual)

## Conditions studied

- Atopic Dermatitis
- Atopic
- Dermatitis
- AD
- Eczema

## Interventions

- **DRUG:** ATI-045
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07011706
- **Lead sponsor:** Aclaris Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2025-05-30
- **Primary completion:** 2026-08
- **Final completion:** 2026-10
- **Target enrollment:** 110 (ACTUAL)
- **Last updated:** 2026-03-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07011706

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07011706, "ATI-045 Versus Placebo in Patients With Moderate-to-Severe Atopic Dermatitis". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT07011706. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*